review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.3389/FNCEL.2014.00369 |
P8608 | Fatcat ID | release_qtnqc5cecjhi5alpcgplqlriri |
P932 | PMC publication ID | 4227512 |
P698 | PubMed publication ID | 25426023 |
P5875 | ResearchGate publication ID | 269660400 |
P50 | author | Hortensia Alonso-Navarro | Q90025041 |
José Agundez | Q42720672 | ||
Elena García-Martín | Q37610485 | ||
P2093 | author name string | Félix J Jiménez-Jiménez | |
P2860 | cites work | Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases | Q28270925 |
The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease | Q28325517 | ||
Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease | Q69098325 | ||
Dipeptidyl-aminopeptidase II in human cerebrospinal fluid: changes in patients with Parkinson's disease | Q69115997 | ||
[Leukotrienes and neurological diseases] | Q69158288 | ||
Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type | Q69381597 | ||
Magnitude of response to levodopa in Parkinson disease as it relates to peripheral and central measurements of levodopa and associated metabolites | Q69425315 | ||
Alteration of amino acids in cerebrospinal fluid from patients with Parkinson's disease and spinocerebellar degeneration | Q69503377 | ||
Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's disease | Q83220912 | ||
Biopterin levels in the cerebrospinal fluid of patients with PARK8 (I2020T) | Q83360391 | ||
CSF markers of neurodegeneration in Parkinson's disease | Q84786273 | ||
Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome | Q85020419 | ||
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects | Q85425444 | ||
Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease | Q88076090 | ||
Hydroxylase Cofactor Activity in Cerebrospinal Fluid of Normal Subjects and Patients with Parkinson's Disease | Q28326297 | ||
Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism | Q28336577 | ||
Study on the concentration of 5-hydroxyindoleacetic acid (5-HIAA) in the lumbar cerebrospinal fluid (CSF) in neurological diseases | Q28340408 | ||
CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis | Q28731571 | ||
Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort | Q30405991 | ||
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease | Q30493811 | ||
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression | Q30501271 | ||
Phosphorylated α-synuclein in Parkinson's disease | Q30510167 | ||
Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease. | Q31823176 | ||
Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease | Q33525158 | ||
Ferritin in the cerebrospinal fluid of patients with Parkinson's disease | Q33589109 | ||
Cerebrospinal fluid arginine vasopressin in degenerative disorders and other neurological diseases | Q33618361 | ||
Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia | Q33622879 | ||
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease | Q33666297 | ||
N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease. | Q33689680 | ||
Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF | Q33756474 | ||
Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis | Q33981403 | ||
CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease | Q33994583 | ||
Urate as a predictor of the rate of clinical decline in Parkinson disease | Q34019732 | ||
Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients | Q34064156 | ||
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease | Q34140382 | ||
1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSF | Q34298649 | ||
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. | Q34299993 | ||
Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia | Q34469280 | ||
Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy | Q34544824 | ||
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy | Q34805505 | ||
Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease | Q34806122 | ||
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function | Q35757332 | ||
Decreased beta-phenylethylamine in CSF in Parkinson's disease | Q36317491 | ||
Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia | Q36384748 | ||
Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease | Q36718213 | ||
Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. | Q36852905 | ||
Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects | Q36925296 | ||
CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease | Q36943074 | ||
Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients | Q42167232 | ||
Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders | Q42202451 | ||
CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease. | Q42274526 | ||
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement | Q42276279 | ||
Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease | Q42276779 | ||
Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment | Q42278983 | ||
Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease | Q42287995 | ||
The glial marker YKL-40 is decreased in synucleinopathies | Q42441318 | ||
Cerebrospinal fluid homovanillic acid levels are not reduced in early corticobasal degeneration | Q42455831 | ||
Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease | Q42472074 | ||
Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease | Q42503236 | ||
Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus | Q42515011 | ||
bcl-2 protein is increased in the brain from parkinsonian patients | Q42526032 | ||
(E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease | Q42541023 | ||
Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders | Q42547717 | ||
Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease | Q42548051 | ||
Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3. | Q42904569 | ||
Polyamine patterns in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy | Q43048638 | ||
Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson's disease. | Q43102395 | ||
L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease | Q43113090 | ||
Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease. | Q43225553 | ||
Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurod | Q43234302 | ||
Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression | Q43257873 | ||
beta-Endorphin cerebrospinal fluid decrease in untreated parkinsonian patients | Q43522910 | ||
Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease | Q43538416 | ||
Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism | Q43547469 | ||
Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. | Q43792598 | ||
Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease | Q43841073 | ||
CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease | Q43844328 | ||
Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy | Q43918307 | ||
Ventricular fluid neuropeptides in Parkinson's disease. I. Levels and distribution of somatostatin-like immunoreactivity | Q44005163 | ||
Increased neopterin production and tryptophan degradation in advanced Parkinson's disease | Q44035901 | ||
Post-proline cleaving enzyme in human cerebrospinal fluid from control patients and parkinsonian patients | Q44101763 | ||
Presence of methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines, derivatives of the neurotoxin isoquinoline, in parkinsonian lumbar CSF. | Q44138760 | ||
Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease | Q44260283 | ||
Opioid peptides in Parkinson's disease: effects of dopamine repletion | Q44335345 | ||
Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease | Q44496527 | ||
Concentrations of 5-Hydroxyindole-acetic Acid and Homovanillic Acid in the Cerebrospinal Fluid after Treatment with Probenecid in Patients with Parkinson's Disease | Q44496744 | ||
Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease | Q44530761 | ||
Concentrations of neopterin and biopterin in the cerebrospinal fluid of patients with Parkinson's disease | Q44610902 | ||
Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. | Q44642324 | ||
Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. | Q44745912 | ||
Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication | Q44748626 | ||
Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. | Q45152977 | ||
Clinical and biochemical features of depression in Parkinson's disease | Q45195312 | ||
Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. | Q45288825 | ||
Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementia | Q45294244 | ||
CSF somatostatin-like immunoreactivity in dementia | Q45296600 | ||
Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea | Q45299155 | ||
Homovanillic acid in the cerebrospinal fluid: studies in Parkinson's syndrome and other diseases of the CNS | Q45301340 | ||
Adenosine 3',5'-monophosphate in cerebrospinal fluid. Effect of drugs and neurologic disease | Q45303235 | ||
Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders | Q45304050 | ||
Gamma-aminobutyric acid (GABA) in cerebrospinal fluid | Q45304767 | ||
Parkinson's disease and benign essential tremor: somatostatin-like immunoreactivity in the cerebrospinal fluid | Q45305074 | ||
Free and conjugated GABA in human cerebrospinal fluid: Effect of degenerative neurologic diseases and isoniazid | Q45305366 | ||
Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders | Q45306051 | ||
Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseases | Q45306983 | ||
CSF biomarkers in different phenotypes of Parkinson disease | Q45753674 | ||
Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease | Q46189772 | ||
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. | Q46456086 | ||
Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease | Q46527170 | ||
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease | Q46802886 | ||
Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease | Q47860357 | ||
Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders | Q47996302 | ||
Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease | Q48122219 | ||
Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease | Q48134664 | ||
Neurotrophins and cytokines in Parkinson's disease. | Q48160124 | ||
Hypocretin (orexin) loss in Parkinson's disease | Q48182911 | ||
Acetyl- and butyrylcholinesterase activity in the cerebrospinal fluid of patients with Parkinson's disease | Q48184947 | ||
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients | Q48191627 | ||
Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy | Q48194683 | ||
CFS hydroxylase cofactor levels in some neurological diseases | Q37000762 | ||
CSF and plasma GABA levels in Parkinson's disease | Q37019862 | ||
Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases | Q37019894 | ||
CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders | Q37057057 | ||
The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa | Q37067896 | ||
Cerebrospinal fluid choline in extrapyramidal disorders | Q37086864 | ||
Interactions of L-dopa and amantadine in patients with Parkinsonism | Q37090984 | ||
An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy | Q37091013 | ||
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy | Q37114685 | ||
May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum α-synuclein serve for diagnosis of sporadic Parkinson's disease? | Q37147697 | ||
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases | Q37208032 | ||
Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease | Q37228718 | ||
The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease | Q37736608 | ||
CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls | Q38145962 | ||
Genomic and pharmacogenomic biomarkers of Parkinson's disease. | Q38201524 | ||
Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study | Q38452068 | ||
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease | Q38641189 | ||
Acetylcholine and choline in cerebrospinal fluid of patients with Parkinson's disease and Huntington's chorea | Q39301729 | ||
Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease | Q39376713 | ||
Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease | Q39411963 | ||
Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies | Q39549489 | ||
Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders | Q39577317 | ||
Brain dopamine turnover and the relief of parkinsonism | Q39581042 | ||
The activity of aminotransferases in serum and cerebrospinal fluid in neurological diseases (author's transl) | Q39761014 | ||
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study | Q39783457 | ||
Cerebrospinal Fluid -Aminobutyric Acid Variations in Neurological Disorders | Q39830791 | ||
Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism | Q40060520 | ||
The effect of L-dopa and propranolol on human CSF cyclic nucleotides | Q40167962 | ||
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease | Q40278884 | ||
Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease | Q40441648 | ||
A case control study of CSF copper, iron and manganese in Parkinson disease | Q41126815 | ||
Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice | Q41164734 | ||
The relationship of serotonin to depression in Parkinson's disease | Q41254642 | ||
A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease | Q41613762 | ||
The role of nitric oxide in neurodegeneration. Potential for pharmacological intervention | Q41757009 | ||
Histamine Metabolites and pros-Methylimidazoleacetic Acid in Human Cerebrospinal Fluid | Q41981306 | ||
Decreased ferritin levels in brain in Parkinson's disease | Q42000755 | ||
Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease | Q42045096 | ||
Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease | Q42144037 | ||
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. | Q51050295 | ||
Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF | Q51107926 | ||
Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease. | Q51112716 | ||
Cerebrospinal fluid levels of 3-methoxy4hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L-DOPA | Q51121463 | ||
Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism | Q51160311 | ||
5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. | Q51211033 | ||
On the Occurrence of Homovanillic Acid and 5-Hydroxyindol-3-ylacetic Acid in the Ventricular C.S.F. of Patients Suffering from Parkinsonism | Q51222870 | ||
Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in parkinsonism. | Q51307459 | ||
Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system | Q51677472 | ||
Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. | Q51892103 | ||
CSF somatostatin increase in patients with early parkinsonian syndrome. | Q52019874 | ||
Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. | Q52056878 | ||
Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. | Q52074381 | ||
Amino acid abnormalities in cerebrospinal fluid and blood serum of patients with Parkinson's disease, other heredodegenerative disorders and head injuries. | Q52548941 | ||
Parkinson's disease and dementia: clinical and neurochemical correlations | Q53179312 | ||
beta-Endorphin-like immunoreactivity in cerebrospinal fluid of patients with Alzheimer's disease and Parkinson's disease. | Q53190554 | ||
Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. | Q53201956 | ||
[Simultaneous determination of catecholamines, serotonin, and their precursors and metabolites in body fluid by an HPLC system with multi-electrode electrochemical detector] | Q53204387 | ||
Concentration of neural thread protein in cerebrospinal fluid from progressive supranuclear palsy and Parkinson's disease. | Q53208366 | ||
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? | Q53212854 | ||
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. | Q53213249 | ||
Determination of acetylcholine concentration in cerebrospinal fluid of patients with neurologic diseases. | Q53213589 | ||
Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. | Q53246758 | ||
Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. | Q53288614 | ||
Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls | Q53292491 | ||
Differential distribution of neuregulin in human brain and spinal fluid. | Q53299220 | ||
Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients. | Q53299881 | ||
[Acetylcholinesterase activity in CSF in senile dementia of Alzheimer type, vascular dementia, and Parkinson's disease] | Q53301778 | ||
Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. | Q53303462 | ||
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method | Q53308312 | ||
Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. | Q53316529 | ||
Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. | Q53337561 | ||
High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease. | Q53417457 | ||
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. | Q53417610 | ||
Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. | Q54359584 | ||
Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes. | Q54587226 | ||
Cerebrospinal fluid corticotropin-releasing hormone in neurodegenerative diseases: reduction in spinocerebellar degeneration. | Q55063207 | ||
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias | Q57750814 | ||
Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia | Q58478217 | ||
Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease | Q58852569 | ||
Tetrahydrobiopterin and Parkinson's disease | Q59549029 | ||
Fe and Cu do not differ in Parkinson's disease: A replication study plus meta-analysis | Q60609983 | ||
CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders | Q63456912 | ||
Methionine enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients | Q64761525 | ||
CSF GABA levels in Parkinson's disease | Q64762967 | ||
Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders | Q64763395 | ||
L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients | Q64781321 | ||
Low CSF GABA in parkinsonian patients who respond poorly to therapy or suffer from the “on-off” phenomenon | Q64781386 | ||
Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases | Q64786329 | ||
[Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)] | Q64787929 | ||
Aging and CSF hydroxylase cofactor | Q64789931 | ||
Decreased concentration of annexin V in parkinsonian cerebrospinal fluid: speculation on the underlying cause | Q64819957 | ||
Oxidative stress indicators are elevated in de novo Parkinson's disease patients. | Q64821241 | ||
R- and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patients | Q64859998 | ||
Cerebrospinal fluid selenium and chromium levels in patients with Parkinson's disease | Q64866262 | ||
Oxidative stress and Parkinson's disease | Q64866398 | ||
No increase of synthesis of (R)salsolinol in Parkinson's disease | Q48198915 | ||
Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy | Q48202209 | ||
Low levels of ventricular CSF orexin/hypocretin in advanced PD. | Q48217719 | ||
Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease | Q48218181 | ||
Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness? | Q48235911 | ||
Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases | Q48260033 | ||
An endogenous MPTP-like dopaminergic neurotoxin, N-methyl(R)salsolinol, in the cerebrospinal fluid decreases with progression of Parkinson's disease | Q48264694 | ||
Low level of ventricular CSF orexin-A is not associated with objective sleepiness in PD. | Q48279820 | ||
Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease | Q48289983 | ||
Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model | Q48327855 | ||
Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia | Q48384242 | ||
The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease | Q48385118 | ||
The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls | Q48386016 | ||
Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease | Q48391021 | ||
Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients | Q48394245 | ||
Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease | Q48402580 | ||
CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration | Q48411834 | ||
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease | Q48438362 | ||
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). | Q48486699 | ||
Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy | Q48509725 | ||
Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients | Q48545459 | ||
Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders | Q48560437 | ||
Lack of changes in ventricular cerebrospinal fluid concentrations of homovanillic acid following acute challenge with levodopa | Q48569190 | ||
Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. | Q48605519 | ||
Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology | Q48629923 | ||
Altered serotonin metabolism in depressed patients with parkinson's disease | Q48680548 | ||
Total biopterin levels in the ventricular CSF of patients with Parkinson's disease: a comparison between akineto-rigid and tremor types | Q48713953 | ||
The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Studies in patients with extrapyramidal disorders, epilepsy, and other diseases | Q48719108 | ||
A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease and spinocerebellar degeneration | Q48719963 | ||
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? | Q48819771 | ||
Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease | Q48822750 | ||
TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid | Q48856015 | ||
Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy | Q48858527 | ||
Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson's disease and other dyskinesias | Q48893374 | ||
Cerebrospinal fluid choline levels are decreased in Parkinson's disease | Q48956570 | ||
Comparison of DSIP- (delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's disea | Q48972190 | ||
Measurement of lumbar CSF levels of met-enkephalin, encrypted met-enkephalin, and neuropeptide Y in normal patients and in patients with Parkinson's disease before and after autologous transplantation of adrenal medulla into the caudate nucleus | Q49074131 | ||
Cerebrospinal fluid nitrate levels in patients with Parkinson's disease | Q49136063 | ||
Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease. | Q50262786 | ||
Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. | Q50596072 | ||
Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. | Q50637977 | ||
Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. | Q50664328 | ||
Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. | Q50711777 | ||
3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. | Q50732857 | ||
Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease. | Q50893237 | ||
Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders. | Q50896980 | ||
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. | Q50940972 | ||
The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. | Q51027167 | ||
??? | Q64767716 | ||
??? | Q64777647 | ||
??? | Q64779261 | ||
??? | Q64781356 | ||
??? | Q64785254 | ||
??? | Q64864260 | ||
??? | Q64878393 | ||
??? | Q64878762 | ||
??? | Q64878784 | ||
??? | Q64891570 | ||
??? | Q64891572 | ||
??? | Q64891583 | ||
??? | Q64900619 | ||
??? | Q64937450 | ||
??? | Q64966069 | ||
Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease | Q64870117 | ||
Free amino acids in the cerebrospinal fluid in old age and in Parkinson's disease | Q64871767 | ||
[Salsolinol, 3-O-methyl-dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients] | Q64917941 | ||
Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease | Q64922770 | ||
5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L-DOPA | Q64942454 | ||
Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa. | Q64961710 | ||
Serial determinations of homovanillinic acid in the cerebrospinal fluid of Parkinson patients treated with L-dopa. | Q67207400 | ||
Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism. | Q67207616 | ||
L-dopa and cerebrospinal fluid homovanillic acid in parkinsonism | Q67213491 | ||
Cerebrospinal fluid carnitine levels in patients with Parkinson's disease | Q67215709 | ||
Cerebrospinal fluid acetylcholine in man | Q67217929 | ||
Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease | Q67218084 | ||
Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patients | Q67218923 | ||
Glutamic oxaloacetic transaminase in serum and cerebrospinal fluid in parkinsonism. | Q67223416 | ||
Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease | Q67225171 | ||
Humoral response to hsp 65 and hsp 70 in cerebrospinal fluid in Parkinson's disease | Q67237611 | ||
A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid | Q67243091 | ||
Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. | Q67243561 | ||
Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy | Q67653142 | ||
Ventricular fluid neuropeptides in Parkinson's disease. II. Levels of substance P-like immunoreactivity | Q67687425 | ||
Neurokinin concentrations in cerebrospinal fluid. A preliminary study in Parkinson's disease | Q67853306 | ||
Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease | Q67996540 | ||
Diazepam binding inhibitor-like immunoreactivity (DBI-LI) in human CSF. Correlations with neurological disorders | Q68002734 | ||
Juvenile parkinsonism: ventricular CSF biopterin levels and clinical features | Q68034459 | ||
Cerebrospinal fluid amino compounds in Parkinson's disease. Alterations due to carbidopa/levodopa | Q68254813 | ||
Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients | Q68633495 | ||
[Drug-induced dyskinesia during the treatment of Parkinson disease--biochemical studies] | Q68958851 | ||
Depression and Parkinson's disease: possible role of serotonergic mechanisms | Q68988930 | ||
Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid | Q69095363 | ||
Beta 2-microglobulin decrease in cerebrospinal fluid from parkinsonian patients | Q69551845 | ||
[The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment] | Q69748784 | ||
Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease | Q69749335 | ||
Cerebrospinal fluid arginine vasopressin in Parkinson's disease, dementia, and other degenerative disorders | Q69771890 | ||
Alpha-melanocyte-stimulating hormonelike immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's disease | Q69842781 | ||
CSF cyclic nucleotides and somatostatin in Parkinson's disease | Q69875138 | ||
Reduced cholecystokinin levels in cerebrospinal fluid of parkinsonian and schizophrenic patients. Effect of ceruletide in schizophrenia | Q69903255 | ||
Raised cerebrospinal-fluid copper concentration in Parkinson's disease | Q69903302 | ||
CSF dopamine-beta-hydroxylase activity in Parkinson's disease | Q70077514 | ||
Cyclic nucleotides in cerebrospinal fluid of drug-free Parkinson patients | Q70191540 | ||
Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease | Q70285006 | ||
The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients | Q70575719 | ||
Vasoactive intestinal peptide in cerebrospinal fluid | Q70598937 | ||
Cerebrospinal fluid choline levels in Parkinson's disease | Q70777485 | ||
Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease | Q70802059 | ||
Nitrite, nitrate and cGMP in the cerebrospinal fluid in degenerative neurologic diseases | Q71370105 | ||
Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease | Q71525806 | ||
Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa | Q71542503 | ||
Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration | Q71603417 | ||
beta-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease | Q71631171 | ||
CSF acetylcholinesterase in Parkinson disease: decreased enzyme activity and immunoreactivity in demented patients | Q71956055 | ||
Concentrations of serotonin and its related substances in the cerebrospinal fluid of Parkinsonian patients and their relations to the severity of symptoms | Q72076551 | ||
Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease | Q72129356 | ||
Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+ | Q72142393 | ||
[Trace elements analysis of serum and cerebrospinal fluid with PIXE--effect of age and changes in parkinsonian patients] | Q72171643 | ||
gamma delta+ T cells are increased in patients with Parkinson's disease | Q72304394 | ||
Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients | Q72304398 | ||
[The effect of droxidopa on the monoamine metabolsim in the human brain] | Q72456444 | ||
Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients | Q73065148 | ||
Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease | Q73533437 | ||
Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease | Q74624169 | ||
Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease | Q74624173 | ||
Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy | Q78828029 | ||
Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's disease | Q79404888 | ||
Polyunsaturated fatty acid levels in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy | Q80165349 | ||
Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease | Q80342694 | ||
Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease | Q80424021 | ||
Elemental profile of cerebrospinal fluid in patients with Parkinson's disease | Q81547777 | ||
Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease | Q82257191 | ||
CSF α-synuclein does not differentiate between parkinsonian disorders | Q83209287 | ||
P921 | main subject | biomarker | Q864574 |
Parkinson's disease | Q11085 | ||
cerebrospinal fluid | Q54196 | ||
P304 | page(s) | 369 | |
P577 | publication date | 2014-11-11 | |
P1433 | published in | Frontiers in Cellular Neuroscience | Q2131509 |
P1476 | title | Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease | |
P478 | volume | 8 |
Q92055253 | Association of LAG3 genetic variation with an increased risk of PD in Chinese female population |
Q58805374 | Bioelemental patterns in the cerebrospinal fluid as potential biomarkers for neurodegenerative disorders |
Q41666702 | Biomarker Research in Parkinson's Disease Using Metabolite Profiling |
Q49942492 | Biomarkers for Parkinson's Disease: Recent Advancement. |
Q40460924 | Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson's disease patients with mild cognitive impairment. |
Q53512696 | Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. |
Q41974638 | Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy |
Q94544384 | Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid |
Q41829630 | Editorial on Cerebral endothelial and glial cells are more than bricks in the Great Wall of the brain: insights into the way the blood-brain barrier actually works (celebrating the centenary of Goldman's experiments). |
Q58084961 | Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis |
Q60949823 | Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease |
Q64228408 | Inflammation, Infectious Triggers, and Parkinson's Disease |
Q60304733 | Metabolomic investigations in cerebrospinal fluid of Parkinson's disease |
Q42380034 | Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance |
Q58572579 | Recent Advances in Biomarkers for Parkinson's Disease |
Q26738420 | Somatostatin and Somatostatin-Containing Neurons in Shaping Neuronal Activity and Plasticity |
Q35783515 | Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease |
Q47712262 | Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease. |
Q92017939 | What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations? |
Search more.